We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

donderdag 12 oktober 2017

The Lancet: [Comment] Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer

[Comment] Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer
Taxane chemotherapy, including docetaxel in the front-line and cabazitaxel in the second-line setting, are mainstays of treatment for metastatic castration-resistant prostate cancer. In the phase 3 AFFINITY trial reported in The Lancet Oncology,1 Tomasz Beer and colleagues investigated whether the addition of custirsen, an antisense oligonucleotide that targets the clusterin chaperone protein, improved overall survival when added to cabazitaxel in patients with metastatic castration-resistant prostate cancer that had progressed after previous docetaxel treatment.
Read more

[Articles] Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
We cannot recommend the use of extended adjuvant aromatase inhibition after 5 years of sequential endocrine therapy in all postmenopausal women with hormone receptor-positive breast cancer.
Read more

[Comment] Extended adjuvant therapy: the role of subset analyses
The report of the DATA trial1 by Vivianne Tjan-Heijnen and colleagues and published in The Lancet Oncology adds to the current body of information delineating the role of extended adjuvant aromatase inhibition in women already treated with tamoxifen followed by an aromatase inhibitor. Women were randomly assigned to treatment after 2–3 years of treatment with adjuvant tamoxifen to either 3 or 6 years of further anastrozole treatment with a primary study endpoint of disease-free survival. Since women in both study groups had a common initial 3-year period of anastrazole treatment, the analysis presented started 3 years after randomisation and is described by the authors as an adapted disease-free survival analysis.
Read more

[News] Oncolytic virus therapy in advanced melanoma
The combination of talimogene laherparepvec, an oncolytic virus, plus ipilimumab could be significantly more effective than ipilimumab alone for treating advanced, unresectable melanoma, according to the results of a recent study.
Read more

[News] Copanlisib in heavily pretreated indolent lymphoma
New research suggests that copanlisib, a selective class I phosphatidylinositol 3-kinase (PI3K) inhibitor that acts by inhibiting PI3K-α and PI3K-δ isoforms, is a safe and efficacious treatment option in heavily pretreated patients with relapsed or refractory indolent lymphoma.
Read more